AVEZ-VOUS DES QUESTIONS? CLIQUEZ ICI
lundi-vendredi: 9:00 - 18:00 (GMT+1)
Samedi-Dimanche fermé
+33 (0) 22802 00 09
Téléphone
5 rue Édouard Belin 44360 Vigneux-de-Bretagne
Adresse

ACTUALITES

After the success of the European program REBORNE (FP7) focused on safety and efficacy of the Biomatlante matrix combined with autologous bone marrow expanded mesenchymal stem cells (MSC), MBCP+™, made from our well-known MBCP Technology, was confirmed as the adapted matrix for tissue engineering and chosen for 2 new European research programs (H2020): MAXIBONE and ORTHOUNION.

Coordinated by INSERM (Institut National de la Santé et de la Recherche Médicale) and with the support of the E.U., the REBORNE Program sought to establish the feasibility, relevance and efficacy of the association of MBCP+™*, a synthetic bone graft manufactured by Biomatlante made from MBCP™ Technology, and Mesenchymal Stem Cells (MSCs)1.

Introduction: Bone is the most transplanted tissue in human with about 1 million procedures annually in Europe. Autologous bone grafting is the gold standard in bone regeneration but it requires a second surgery, is limited in quantity and often associated with painful complications. Synthetic calcium phosphate biomaterial in association with mesenchymal stem cells may be a potent alternative to autologous bone grafting.

Emmanuel Macron, minister of Economy, met May 18, 2015 in Nantes, with the actors mobilized for the reindustrialization project “the Industry of the Future”, new array of industrial strategy. On its way to play a mainly role in the phase II of New Industrial France (NFI), this project aims to modernize the industrial tool and transform its business model by digital.

biomatlante---logo-mbcp-technology---png-white-colours.png


Advance Medical Solutions Logo

Nos produits

Groupe AMS

Choisissez une langue

Liens utiles

Suivez-Nous

© Copyright 2024 Biomatlante. All Rights Reserved.

Search